BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins^TM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

"The addition of Roche, a global leader and innovator, to our family of collaborators underscores BIND's unique, leading position in the field of nanomedicine,," said Scott Minick, Chief Executive Officer of BIND Therapeutics. "By combining BIND's Medicinal Nanoengineering^® platform with Roche's deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas."